| Filed On | Filing |
|---|---|
| 16 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 05 Oct 2026 |
Form 4: Guerard Frederic, Director
Granted 20,000 Director Stock Option (Right to Buy) |
| 05 Oct 2026 |
Form 4: Glicklich Alan, Director
Granted 20,000 Director Stock Option (Right to Buy) |
| 05 Oct 2026 |
Form 4: Zaytsev Evgeny, Director
Granted 20,000 Director Stock Option (Right to Buy) |
| 05 Oct 2026 |
Form 4: Shaw Allan, Director
Granted 20,000 Director Stock Option (Right to Buy) |
| 05 Oct 2026 |
Form 4: Wilson Robert N, Director
Granted 20,000 Director Stock Option (Right to Buy) |
| 30 Sep 2026 | 424B5 |
| 30 Sep 2026 |
8-K: Other Events
We have acted as counsel to CalciMedica, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of shares of its common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offeri... |
| 28 Sep 2026 |
Form 4: Stauderman Kenneth A., Chief Scientific Officer
Granted 180,000 Employee Stock Option (Right to Buy) |
| 28 Sep 2026 |
Form 4: Hebbar Sudarshan, Chief Medical Officer
Granted 180,000 Employee Stock Option (Right to Buy) |
| 28 Sep 2026 |
Form 4: Bardin Stephen, Chief Financial Officer
Granted 190,000 Employee Stock Option (Right to Buy) |
| 28 Sep 2026 |
Form 4: Leheny A. Rachel, Director
Granted 360,000 Employee Stock Option (Right to Buy) |
| 23 Sep 2026 | S-8 |
| 16 Sep 2026 |
8-K: Other Events
As previously disclosed, on March 16, 2026, CalciMedica, Inc. (the “Company”) received notice (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was n... |
| 02 Sep 2026 | 8-K: Other Events |
| 27 Aug 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year |
| 25 Aug 2026 | SCHEDULE 13G |
| 24 Aug 2026 |
Form 4: Alafi Capital Co Llc, 10% owner
Granted 3,529,192 Series A Warrants · Granted 3,529,192 Series B Warrants |
| 24 Aug 2026 | SCHEDULE 13D/A |
| 21 Aug 2026 |
Form 4: Shaw Allan, Director
Granted 10,000 Director Stock Option (Right to Buy) |
Loading...
